Page 1 | Search Results | Blood Advances | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Impact of type of induction therapy on outcomes in older adults with AML after allogeneic stem cell transplantation

Blood Adv (2023) 7 (14): 3573–3581.

https://doi.org/10.1182/bloodadvances.2022009632

Published: 2023

Includes: Supplemental data

Journal Articles

Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensity

Blood Adv (2023) 7 (13): 3284–3296.

https://doi.org/10.1182/bloodadvances.2022009391

Published: 2023

Includes: Supplemental data

Journal Articles

BH3 profiling identifies BCL-2 dependence in adult patients with early T-cell progenitor acute lymphoblastic leukemia

Elyse A. Olesinski, Karanpreet S. Bhatia, Aarthi N. Mahesh, Shazwina Rosli, Jameelah S. Mohamed, Wei Y. Jen, Nitin Jain, Jacqueline S. Garcia, Gee C. Wong, Melissa Ooi, Anthony Letai, Marina Konopleva, Shruti Bhatt

Blood Adv (2023) 7 (12): 2917–2923.

https://doi.org/10.1182/bloodadvances.2022007728

Published: 2023

Includes: Supplemental data

Journal Articles

TET2 truncating mutations predict a worse outcome in blastic plasmacytoid dendritic cell neoplasm

Hannah Beird, C. Cameron Yin, Joseph D. Khoury, Sherry Pierce, Hussein A. Abbas, Li Zhao, Anna Skwarska, Muzaffar Qazilbash, Marina Konopleva, P. Andrew Futreal, Naveen Pemmaraju

Blood Adv (2023) 7 (10): 2000–2003.

https://doi.org/10.1182/bloodadvances.2022007879

Published: 2023

Includes: Supplemental data

Journal Articles

A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL

Blood Adv (2023) 7 (10): 1958–1966.

https://doi.org/10.1182/bloodadvances.2022008790

Published: 2023

Includes: Supplemental data

Journal Articles

Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML

Blood Adv (2023) 7 (6): 933–942.

https://doi.org/10.1182/bloodadvances.2022008316

Published: 2023

Includes: Supplemental data

Journal Articles

Validation of the ALFA-1200 model in older patients with AML treated with intensive chemotherapy

Hussein A. Abbas, Hanxiao Sun, Sherry Pierce, Rashmi Kanagal-Shamanna, Ziyi Li, Musa Yilmaz, Gautam Borthakur, Adam J. DiPippo, Elias Jabbour, Marina Konopleva, Nicholas J. Short, Courtney DiNardo, Naval Daver, Farhad Ravandi, Tapan M. Kadia

Blood Adv (2023) 7 (5): 828–831.

https://doi.org/10.1182/bloodadvances.2022007172

Published: 2023

Includes: Supplemental data

Journal Articles

Validation of ALFA 1200 score in patients with AML >60 years treated with double nucleoside–based low-intensity therapy

Sangeetha Venugopal, Gautam Borthakur, Naval Daver, Courtney D. DiNardo, Naveen Pemmaraju, Nicholas J. Short, Hussein A. Abbas, Guillermo Garcia-Manero, Marina Konopleva, Farhad Ravandi, Tapan M. Kadia

Blood Adv (2022) 6 (19): 5546–5549.

https://doi.org/10.1182/bloodadvances.2021006689

Published: 2022

Journal Articles

High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse

Blood Adv (2022) 6 (13): 4006–4014.

https://doi.org/10.1182/bloodadvances.2022007378

Published: 2022

Includes: Supplemental data

Journal Articles

Characteristics and outcomes of patients with blastic plasmacytoid dendritic cell neoplasm treated with frontline HCVAD

Naveen Pemmaraju, Nathaniel R. Wilson, Guillermo Garcia-Manero, Koji Sasaki, Joseph D. Khoury, Nitin Jain, Gautam Borthakur, Farhad Ravandi, Naval Daver, Tapan Kadia, Courtney DiNardo, Elias Jabbour, Sherry Pierce, Muzaffar Qazilbash, Marina Konopleva, Hagop Kantarjian

Blood Adv (2022) 6 (10): 3027–3035.

https://doi.org/10.1182/bloodadvances.2021006645

Published: 2022

Includes: Supplemental data

Journal Articles

Single-cell polyfunctional proteomics of CD4 cells from patients with AML predicts responses to anti–PD-1–based therapy

Hussein A. Abbas, Zoe Alaniz, Sean Mackay, Matthew Cyr, Jing Zhou, Ghayas C. Issa, Mansour Alfayez, Jairo Matthews, Steven M. Kornblau, Elias Jabbour, Guillermo Garcia-Manero, Marina Konopleva, Michael Andreeff, Naval Daver

Blood Adv (2021) 5 (22): 4569–4574.

https://doi.org/10.1182/bloodadvances.2021004583

Published: 2021

Includes: Supplemental data

Journal Articles

Exogenous mitochondrial transfer and endogenous mitochondrial fission facilitate AML resistance to OxPhos inhibition

Blood Adv (2021) 5 (20): 4233–4255.

https://doi.org/10.1182/bloodadvances.2020003661

Published: 2021

Includes: Supplemental data

Journal Articles

Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs

Lucia Masarova, Courtney D. DiNardo, Prithviraj Bose, Naveen Pemmaraju, Naval G. Daver, Tapan M. Kadia, Helen T. Chifotides, Lingsha Zhou, Gautam Borthakur, Zeev Estrov, Marina Konopleva, Srdan Verstovsek

Blood Adv (2021) 5 (8): 2156–2164.

https://doi.org/10.1182/bloodadvances.2020003934

Published: 2021

Includes: Supplemental data

Journal Articles

Prognostic impact of complete remission with MRD negativity in patients with relapsed or refractory AML

Nicholas J. Short, Hind Rafei, Naval Daver, Hyunsoo Hwang, Jing Ning, Jeffrey L. Jorgensen, Tapan M. Kadia, Courtney D. DiNardo, Sa A. Wang, Elias Jabbour, Uday Popat, Betul Oran, Jorge Cortes, Marina Konopleva, Musa Yilmaz, Ghayas C. Issa, Hagop Kantarjian, Farhad Ravandi

Blood Adv (2020) 4 (24): 6117–6126.

https://doi.org/10.1182/bloodadvances.2020002811

Published: 2020

Includes: Supplemental data

Journal Articles

Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia

Nicholas J. Short, Guillermo Montalban-Bravo, Hyunsoo Hwang, Jing Ning, Miguel J. Franquiz, Rashmi Kanagal-Shamanna, Keyur P. Patel, Courtney D. DiNardo, Farhad Ravandi, Guillermo Garcia-Manero, Koichi Takahashi, Marina Konopleva, Naval Daver, Ghayas C. Issa, Michael Andreeff, Hagop Kantarjian, Tapan M. Kadia

Blood Adv (2020) 4 (22): 5681–5689.

https://doi.org/10.1182/bloodadvances.2020003120

Published: 2020

Includes: Supplemental data

Journal Articles

Outcome of patients with IDH1/2- mutated post–myeloproliferative neoplasm AML in the era of IDH inhibitors

Helen T. Chifotides, Lucia Masarova, Mansour Alfayez, Naval Daver, Yesid Alvarado, Elias Jabbour, Marina Konopleva, Hagop M. Kantarjian, Keyur P. Patel, Courtney D. DiNardo, Srdan Verstovsek

Blood Adv (2020) 4 (21): 5336–5342.

https://doi.org/10.1182/bloodadvances.2020001528

Published: 2020

Journal Articles

Approval of tagraxofusp-erzs for blastic plasmacytoid dendritic cell neoplasm

Naveen Pemmaraju, Marina Konopleva

Blood Adv (2020) 4 (16): 4020–4027.

https://doi.org/10.1182/bloodadvances.2019000173

Published: 2020

Journal Articles

Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens

Blood Adv (2020) 4 (7): 1311–1320.

https://doi.org/10.1182/bloodadvances.2019001267

Published: 2020

Includes: Supplemental data

Journal Articles

Genomic context and TP53 allele frequency define clinical outcomes in TP53 -mutated myelodysplastic syndromes

Blood Adv (2020) 4 (3): 482–495.

https://doi.org/10.1182/bloodadvances.2019001101

Published: 2020

Includes: Supplemental data

Journal Articles

NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy

Blood Adv (2019) 3 (6): 922–933.

https://doi.org/10.1182/bloodadvances.2018026989

Published: 2019

Includes: Supplemental data

NARROW

Impact of type of induction therapy on outcomes in older adults with AML after allogeneic stem cell transplantation

Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensity

BH3 profiling identifies BCL-2 dependence in adult patients with early T-cell progenitor acute lymphoblastic leukemia

TET2 truncating mutations predict a worse outcome in blastic plasmacytoid dendritic cell neoplasm

A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL

Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML

Validation of the ALFA-1200 model in older patients with AML treated with intensive chemotherapy

Validation of ALFA 1200 score in patients with AML >60 years treated with double nucleoside–based low-intensity therapy

High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse

Characteristics and outcomes of patients with blastic plasmacytoid dendritic cell neoplasm treated with frontline HCVAD

Single-cell polyfunctional proteomics of CD4 cells from patients with AML predicts responses to anti–PD-1–based therapy

Exogenous mitochondrial transfer and endogenous mitochondrial fission facilitate AML resistance to OxPhos inhibition

Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs

Prognostic impact of complete remission with MRD negativity in patients with relapsed or refractory AML

Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia

Outcome of patients with IDH1/2- mutated post–myeloproliferative neoplasm AML in the era of IDH inhibitors

Approval of tagraxofusp-erzs for blastic plasmacytoid dendritic cell neoplasm

Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens

Genomic context and TP53 allele frequency define clinical outcomes in TP53 -mutated myelodysplastic syndromes

NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only